Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.31 - $0.73 $247 - $582
-798 Reduced 0.86%
91,545 $37,000
Q4 2022

Feb 13, 2023

SELL
$0.27 - $5.75 $69 - $1,483
-258 Reduced 0.28%
92,343 $26,000
Q2 2022

Aug 12, 2022

BUY
$0.6 - $1.14 $993 - $1,886
1,655 Added 1.82%
92,601 $74,000
Q4 2021

Feb 11, 2022

SELL
$1.27 - $2.08 $16,772 - $27,470
-13,207 Reduced 12.68%
90,946 $117,000
Q3 2021

Nov 12, 2021

BUY
$1.73 - $5.3 $92,802 - $284,307
53,643 Added 106.2%
104,153 $213,000
Q2 2021

Aug 13, 2021

BUY
$1.57 - $2.45 $30,220 - $47,160
19,249 Added 61.58%
50,510 $103,000
Q1 2021

May 12, 2021

BUY
$2.01 - $3.5 $36,334 - $63,269
18,077 Added 137.11%
31,261 $68,000
Q4 2020

Feb 12, 2021

BUY
$0.79 - $3.17 $10,415 - $41,793
13,184 New
13,184 $26,000

About Xenetic Biosciences, Inc.


  • Ticker XBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,166,600
  • Market Cap $64.6M
  • Description
  • Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-base...
More about XBIO
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.